Dark Matter Blog

JULY 16, 2021

As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. Arrakis is the capstone of my career.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Drug Target Review

DECEMBER 7, 2023

Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. The novel, hairpin-shaped molecule was named cabRNA for CBASS-activating bacteriophage RNA.

RNA 59

RNA Immune Response DNA Molecular Biology 59

The Pharma Data

JANUARY 19, 2021

A range of companies are exploring potential gene editing therapies based on a CRISPR-Cas9 system, and the ability to tune the CRISPR cut could prevent off-target editing or control the degree of a target protein’s production. The authors found that tracr-L redirects Cas9 in S. The authors suggest natural tracr-L regulates autoimmunity.

Research 52

Research RNA Molecular Biology Small Molecule 52

Dark Matter Blog

JULY 19, 2021

Or should I say back to retirement, as he was comfortably relaxing at home back in 2016 when Jen Petter lured him back into the fray with the siren call of developing a new class of RNA-targeted small-molecule medicines here at Arrakis. Here’s to many happy and productive years with Sue, Julia, Zooey, and all your guitars!

Small Molecule 52

Small Molecule RNA Science Therapies 52

Sygnature Discovery

JUNE 17, 2024

Our skilled protein science team can provide in-house production of proteins to support all these assay formats if needed. Microscale Thermophoresis (MST) Microscale Thermophoresis (MST) is a technology that uses fluorescently labelled proteins to analyse small molecule binding in solution.

Small Molecule 52

Small Molecule Fragment Screening DNA Science 52

The Pharma Data

OCTOBER 14, 2020

is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

The Pharma Data

DECEMBER 21, 2020

Galidesivir treatment was associated with a more rapid decline in viral RNA levels in the respiratory tract in an apparent dose-dependent manner. About Galidesivir (BCX4430) Galidesivir, a broad-spectrum antiviral drug, is an adenosine nucleoside analog that acts to block viral RNA polymerase.

Clinical Trials 52

Clinical Trials Virus RNA Trials 52

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

Codon

JUNE 11, 2024

Their solution was to fuse hairpins, little loops made from RNA or DNA, at various positions along the DNA strand that was being sequenced. Small molecules can randomly transit through the pore and create disruptions, and the polymerase ratchet mechanism is imperfect, occasionally causing DNA to temporarily reverse direction through the pore.

DNA 91

DNA Engineering RNA Small Molecule 91

The Pharma Data

MARCH 23, 2022

Back in 2018, researchers tested a broad-spectrum antiviral candidate called remdesivir/VEKLURY, which acts as a nucleotide decoy to get incorporated into the viral RNA genome and stop viral polymerase. But targeting Ebola virus polymerase has proven tough. “We weren’t expecting to see this,” says Fang.

Virus 52

Virus Small Molecule Protein Production Research 52

Alta Sciences

APRIL 17, 2024

Our preclinical and bioanalytical experts have extensive experience in leading-edge technologies to support sponsors in the advancement of their gene therapy products. Gene Therapy resources Watch our on-demand webinar, “ Nonclinical Safety Assessment for Gene Therapy Products ”.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

New Drug Approvals

SEPTEMBER 23, 2024

Target: DNA/RNA Synthesis Pathway: Cell Cycle/DNA Damage Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder of the brain, having symptoms characterized by involuntary movements, cognitive impairment, and mental deterioration. SCHEME PATENT PTC Therapeutics Inc., SCHEME PATENT PTC Therapeutics Inc.,

Small Molecule 57

Small Molecule RNA DNA Disease 57

Dark Matter Blog

APRIL 8, 2020

Most people, and in particular most investors we spoke to in those early days, thought we were nuts – that RNA lacked the structural and molecular complexity that medicinal chemistry exploits with such great effect for proteins. One is that molecular recognition is purely a matter of physics and RNA has to play by the same rules.

RNA 52

RNA Small Molecule Synthetic Chemistry Science 52

The Pharma Data

OCTOBER 21, 2020

AT-527 is expected to be ideally suited to combat COVID-19 as it inhibits viral replication by interfering with viral RNA polymerase, a key component in the replication machinery of RNA viruses. Importantly, the manufacturing process for our small molecule direct-acting antiviral allows us to produce AT-527 quickly and at scale.”.

RNA 52

RNA Pharmaceuticals Virus Clinical Trials 52

New Drug Approvals

SEPTEMBER 29, 2024

link] 01 Aug 2022 Cortexyme is now called Quince Therapeutics You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. In the same study, they show that in mice, oral P.

Small Molecule 62

Small Molecule DNA Disease Trials 62

Codon

APRIL 2, 2023

Read A new DNA polymerase variant, called RT-KTq I614Y, can directly detect RNA modifications, including pseudouridine (Ψ) and queuosine (Q). By combining this new variant with standard sequencing methods, it’s possible to identify RNA modifications in a really simple way. Nucleic Acids Research. Communications Biology.

DNA 52

DNA RNA Engineering Licensing 52

Codon

MARCH 20, 2023

Basic Science A trailing ribosome speeds up RNA polymerase at the expense of transcript fidelity via force and allostery. Point-of-care peptide hormone production enabled by cell-free protein synthesis. Marine biofilm engineered to produce current in response to small molecules. Signal Transduction and Targeted Therapy.

Virus 52

Virus Engineering RNA Small Molecule 52

The Pharma Data

MARCH 4, 2021

I would like to thank Ovid for their thoughtful and productive collaboration. The new agreement is expected to close by end of March 2021, subject to the satisfaction of customary closing conditions, including review by the appropriate regulatory agencies under the Hart-Scott-Rodino Act. “I President of Research and Development at Takeda.

Treatment 52

Treatment Clinical Trials Pharmaceutical Companies Trials 52

Broad Institute

SEPTEMBER 23, 2024

Using what they learned from these experiments, they developed a framework — ligation-enabled messenger RNA-oligonucleotide assembly, or LEGO — that enables researchers to chemically modify the structure of mRNA molecules and influence their interactions with the cell's protein-translation machinery, achieving desired therapeutic effects.

RNA 134

RNA Vaccine Small Molecule Therapies 134

The Pharma Data

AUGUST 3, 2021

– Revenue from all key products grew in the quarter and 2021 year-to-date. The company and MiNA Therapeutics Limited announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform. Business Development/Other Developments.

Production 52

Production Marketing Research DNA 52

Conversations in Drug Development Trends

MAY 30, 2024

was withdrawn, rendering it unapproved for patient use, based on negative review comments by the Committee for Medicinal Products for Human Use. Other researchers are investigating approaches that use AAV-mediated trophic support and antibody-based therapies, such as vaccines and small molecule drugs, to modify various protein expressions.

Treatment 81

Treatment Clinical Trials Small Molecule Therapies 81

The Pharma Data

JUNE 26, 2021

BNT111 is the lead product candidate from BioNTech’s FixVac platform that targets a fixed combination of mRNA-encoded, tumor-associated antigens with the objective of triggering a strong and precise immune response against cancer and is fully owned by BioNTech. .” These results were published in Nature in July 2020.

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52

Codon

AUGUST 27, 2024

When doctors sequenced the DNA and RNA found in Alice’s blood and synovial fluid—the liquid that surrounds and lubricates joints—they found abnormally low levels of genes encoding iron-storing proteins and high levels of epidermal growth factor receptor RNA. But DNA alone is not always enough to identify a pathogen.

DNA 106

DNA Laboratories Hospitals Virus 106

The Pharma Data

DECEMBER 27, 2020

Galidesivir is a broad-spectrum antiviral, an adenosine nucleoside analog that blocks viral RNA polymerase. STP705 is a small interfering RNA (siRNA) therapy that leverages a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to knock down both TGF-beta1 and COX-2 gene expression.

Trials 52

Trials Clinical Trials Therapies RNA 52

Codon

DECEMBER 12, 2024

DNA and RNA molecules are also built from exclusively right-handed nucleic acids. Glucose is a chiral molecule because its structure allows for two distinct configurations, or enantiomers, which cannot be superimposed on each other. The mirrored enzyme seamlessly transcribed 2,900 bases of mirrored DNA into mirrored RNA.

RNA 104

RNA DNA Vaccine Virus 104

Codon

MAY 30, 2023

The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. A particular variant, named IscB*-ωRNA*, had the highest editing efficiency across multiple different sites in the genome. Read more in Nature Methods. coli cells.

DNA 52

DNA RNA Engineering Vaccine 52

Codon

MAY 30, 2023

The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. A particular variant, named IscB*-ωRNA*, had the highest editing efficiency across multiple different sites in the genome. Read more in Nature Methods. coli cells.

DNA 52

DNA RNA Engineering Vaccine 52

Codon

APRIL 16, 2023

Read Easy modular integrative fuSion-ready Expression (Easy-MISE) toolkit for fast engineering of heterologous productions in Saccharomyces cerevisiae. Read An RNA-based system to study hepatitis B virus replication and evaluate antivirals. Read [Comment] Delivering the next generation of cancer immunotherapies with RNA.

Engineering 52

Engineering DNA RNA Science 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. For more information, visit. www.merck.com. and connect with us on.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

Codon

APRIL 8, 2025

Experiments performed with the bacterium Streptococcus pneumoniae not only led to the discovery of DNA as the principal hereditary molecule but also yielded early tools for genetic engineering. The study of RNA tumor viruses revealed reverse transcriptase , an enzyme integral in studying RNA biology.

RNA 93

RNA DNA Laboratories Virus 93

Codon

MARCH 26, 2023

Intel’s first product: the 3101 Schottky random-access memory (1969). Link Experimental Tests of the Virtual Circular Genome Model for Nonenzymatic RNA Replication. Link Single-molecule visualization of stalled replication-fork rescue by the Escherichia coli Rep helicase. ” — Gordon Moore Subscribe! Mimoso C.A.

DNA 52

DNA Engineering RNA Science 52